GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
It provides an option to automatically perform nodule detection immediately after chest X-ray imaging
Acute therapies continue to report strong growth compared to chronic ones.
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
It plans to double its network to 50 centres across India in the next three years
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Combination of hardware and data analytics software improves real-time and remote patient monitoring; digitizes and automates time-consuming and critical tasks for medical personnel, reducing administrative tasks by 35 per cent
This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Subscribe To Our Newsletter & Stay Updated